Working... Menu

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01819389
Recruitment Status : Completed
First Posted : March 27, 2013
Last Update Posted : January 7, 2014
Novartis Pharmaceuticals
Information provided by (Responsible Party):
David Gomez Almaguer, Hospital Universitario Dr. Jose E. Gonzalez

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2013
  Actual Study Completion Date : August 2013
Publications automatically indexed to this study by Identifier (NCT Number):